Start up. Grow up. Succeed.

News 2017

Exasol lands in France with new office

Exasol, London – 15th November 2017 – Exasol, the provider of the world’s fastest in-memory analytic database, today announced the opening of its Paris, France office. Building on bases in Germany and the UK, the France office will ...

Immunic Therapeutics Successfully Completes two Phase 1 Studies for IMU-838

Two phase 1 studies for IMU-838 in healthy volunteers have been completed Compound was safe and well tolerated at all doses tested New dosing regimen was determined allowing safe administration of higher doses Planegg-Martinsried, Germany, December 12th...

BioNTech Honored as WuXi AppTec Biotech Company of the Year at Scrip Awards 2017

Mainz, Germany, November 30, 2017 – BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that it has received the WuXi AppTec Biotech Company of the Year Award at the 2017 Scrip Awards cere...

Topas Therapeutics extends its Series A to EUR 18 Million (USD 21 Million) with Boehringer Ingelheim Venture Fund

Corporate venture fund invests EUR 4 million (USD 5 million) into Topas Financing to accelerate clinical trials in autoimmune diseases Detlev Mennerich, Ph.D., Investment Manager of BIVF, to join Topas’ Board ofDirectors Hamburg, 2 November ...

Collaboration project agreement between MAB Discovery GmbH and BioNTech AG

Neuried, Germany - November 6, 2017: MAB Discovery GmbH today announced that it has entered into the second collaboration project agreement with BioNTech AG, Mainz. The unique MAB Discovery technology platform for the generation of novel antibody therapeutic...

AMSilk and Interpolymer Announce Production and Distribution Partnership

Planegg, October 18, 2017 – AMSilk GmbH, the world’s first industrial supplier of synthetic silk biopolymers, and Interpolymer/Zschimmer & Schwarz GmbH Co. KG Chemische Fabriken, a Germany-based global polymer manufacturer, have strengthened th...

Daimler acquires dynamic ridesharing pioneer flinc

flinc is a pioneer in the provision of real-time ridesharing services With the acquisition, Daimler further expands its portfolio of innovative mobility services Unlike traditional carpooling platforms, flinc mediates short journeys dynamically and from do...

BioNTech AG Enters into Licensing Agreement with CELLSCRIPT, LLC as it Advances Development of Messenger RNA Encoding Bispecific Antibodies and other Therapeutic Proteins

Mainz, Germany, September 06, 2017 – BioNTech AG, a fully integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that it has entered into a broad and comprehensive non-exclusive patent licensing agreement with CE...

Immunic Therapeutics Adds New Investors and Completes Series A Financing Round of Total EUR 31.7 Million

Omega and Fund+ broaden Immunic’s investor base and add an additional EUR 10 million(USD 12 million) in equity financing Series A financing round now completed with an overall investment size of EUR 31.7million (USD 37.5 million) – resulting in ...

DPE sells Elevion GmbH to Czech ČEZ Group

Total output increased from 60 million Euro to more than 330 million Euro under DPE ownership / More than 30 strategic acquisitions / Elevion will expand service portfolio into energy related sectors

Nature Publication Reports Favorable Clinical Trial Results of BioNTech's Individualized Cancer Vaccine IVAC® MUTANOME

First-ever clinical study demonstrates personalized RNA-based vaccine using mutant neo-epitopes as antigens activates immune system against individual mutations and exerts anti-cancer activity.

Nature Medicine reports eliminationI of large tumors in mice by messenger RNA-encoded bispecific antibodies

Novel mRNA-based antibody drug class holds promise for fast development of potent immunotherapies.

AMSilk strengthens Business Development team and competence

AMSilk GmbH, the world's first industrial supplier of synthetic silk biopolymers has further expanded its Business Development Unit.

Ethris Adds Three New Members to its Board of Directors Leon Chen, Thomas Chalberg and Justin Duckworth Join Ethris' Board to Support Next Stage of Company's Development

Ethris GmbH, a pioneer in the emerging field of messenger RNA (mRNA) therapies, announced today the addition of Dr. Leon Chen, Venture Partner with OrbiMed, Dr. Thomas Chalberg, COO of Oncorus, Inc. and Justin Duckworth, Managing Partner with HS Life Sciences, to the Ethris Board of Directors.

4A Biotech Co., Ltd. and PEPperPRINT sign distribution agreement for China

We are pleased to announce that PEPperPRINT has signed a distribution agreement with 4A Biotech Co., Ltd. Under the terms of the agreement 4A Biotech Co., Ltd.

4A Biotech Co., Ltd. and PEPperPRINT sign distribution agreement for China

We are pleased to announce that PEPperPRINT has signed a distribution agreement with 4A Biotech Co., Ltd. Under the terms of the agreement 4A Biotech Co., Ltd.

Pieris Pharmaceuticals Announces Expiration of HSR Waiting Period for Collaboration with AstraZeneca

Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer.

Pieris Pharmaceuticals Announces Expiration of HSR Waiting Period for Collaboration with AstraZeneca

Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer.

SYNIMMUNE GmbH Initiates First-in-Human Study of Fc-Optimized Antibody FLYSYN for the Treatment of Acute Myeloid Leukemia

SYNIMMUNE GmbH, a biotechnology company focusing on the development of innovative and effective anti-tumor antibodies for orphan hematopoietic malignancies, announced today that the Company has recently initiated a first-in-human clinical study of FLYSYN, a novel Fc-optimized antibody, for the treatment of acute myeloid leukemia (AML).

Cardior Pharmaceuticals raises €15 million and appoints CEO and CSO

Hannover, Germany, May 11th 2017 – Cardior Pharmaceuticals, today announced the completion of a €15 million Series A financing round led by LSP (Life Sciences Partners), Boehringer Ingelheim Venture Fund (BIVF), Bristol-Myers Squibb (BMS), BioMedPartners (with its new BioMedInvest III Fund) and High-Tech Gründerfonds (HTGF).

Lophius Biosciences Completes Extension of its Financing Round to €7.36 Million

Lophius Biosciences GmbH today announced the extension of the first tranche of the recently closed financing round by €5.2m to €7.4m.

Rentschler and Leukocare announce strategic allianceand equity investment

Rentschler Biotechnologie GmbH, Laupheim and Leukocare AG, Martinsried today announced a strategic alliance under which Leukocare will become the specialized technology partner and the exclusive formulation developer for Rentschler's biopharmaceuticals business.

Nekoosa, A Wingate Partners Portfolio Company, Acquires ClingZ, Continuing Its Product Portfolio Growth

On January 5, 2017, Nekoosa acquired the business and assets of ClingZ, Inc., a Rio Rancho, NM based manufacturerof premium graphic media.

Atriva receives seed financing to develop its next generation influenza therapeutic

The next generation of Antiviral Therapies: Led by Stichting Participatie Atriva together with High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received seed financing from Dutch and German private investors to advance Atriva's antiviral MEK-Inhibitors (Mitogen-activated protein kinase kinase inhibitor) against Influenza into the clinical development stage.

adidas Unveils World's First Performance Shoe Made From AMSilk's Biosteel® Fiber

- The adidas Futurecraft Biofabric features include being 100% biodegradable through a fully natural process - adidas has partnered with AMSilk for the first premium innovation footwear made using silk biopolymers - Concept shoe unveiled at renowned Biofabricate Conference in New YorkPlanegg / New York

Ascendis Pharma Completes $60M Series D Financing

Ascendis Pharma A/S, a Hellerup, Denmark- Palo Alto, California- and Heidelberg, Germany-based biotechnology company, completed a $60m Series D financing.

Immunic Adds EUR 4 Million in Funding to Further Boost Development

• Series A financing round extended to EUR 21.7 Million • Immunic’s investor base broadened by IBG fund which is managed by bmp Beteiligungsmanagement • Expanded funding accelerates further development of IMU-838 and IMU-366 in chronic inflammatory and autoimmune diseases